NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
Clinical Trials
49 trialsNCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT03458247 2025-09-05
OPTIMABI
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02025010 2025-04-15
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01309672 2025-02-26
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01717053 2022-10-10
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Duke University
Phase 2 Completed
NCT02789878 2022-09-15
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT03279250 2022-08-10
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02849990 2022-01-13
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
University of Washington
Phase 2 Completed
NCT02737332 2021-11-22
STAAR
Sun Pharmaceutical Industries Limited
Phase 2 Completed
NCT01751451 2021-11-19
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02962284 2021-11-19
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSAâ„¢
Sun Pharmaceutical Industries Limited
Phase 2 Completed
NCT01503229 2021-05-14
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
Phase 2 Completed
NCT02867852 2021-03-03
SG-ABI14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01842321 2021-02-23
AMA
UNICANCER
Phase 2 Completed
NCT03418324 2020-12-30
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT01940276 2020-12-09
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
Duke University
Phase 2 Completed
NCT01576172 2020-11-12
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01637402 2020-08-17
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT02125357 2020-08-07
Sequencing Abiraterone and Enzalutamide in mCRPC
British Columbia Cancer Agency
Phase 2 Completed
NCT02077634 2020-03-18
SPARE
Universität des Saarlandes
Phase 2 Completed
NCT01946165 2019-12-06
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02034552 2019-07-23
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Bayer
Phase 2 Completed
NCT01543776 2019-07-05
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
University of Chicago
Phase 2 Completed
NCT01867710 2019-07-05
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
Janssen Pharmaceutica N.V., Belgium
Phase 2 Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT01487863 2019-03-19
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT01685983 2019-03-15
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01553188 2019-03-05
AMG 386 and Abiraterone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02097303 2018-02-01
eRADicAte
Carolina Research Professionals, LLC
Phase 2 Completed
NCT01023061 2017-06-06
RAD1
University of Washington
Phase 2 Completed
NCT00544440 2014-07-17
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT00474383 2014-05-12
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT00485303 2013-07-02
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT00924469 2013-04-17
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed